Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer
-
Published:2022-04
Issue:
Volume:165
Page:116-124
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Antoniotti Carlotta, Marmorino Federica, Boccaccino AlessandraORCID, Martini SilviaORCID, Antista Maria, Rossini Daniele, Zuco Valentina, Prisciandaro MicheleORCID, Conca VeronicaORCID, Zucchelli Gemma, Borelli Beatrice, Cosentino Paola, Germani Marco M., Bosco Maria F., Carullo MartinaORCID, Vetere GuglielmoORCID, Moretto RobertoORCID, Giordano Mirella, Masi GianlucaORCID, Pietrantonio Filippo, Zaffaroni Nadia, Cremolini Chiara
Subject
Cancer Research,Oncology
Reference24 articles.
1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016 2. Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline;Chiorean;J Clin Oncol Global Oncol,2020 3. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumour activity;Wilhelm;Int J Cancer,2011 4. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumour activity in mouse models;Tanaka;Oncol Rep,2014 5. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial;Grothey;Lancet,2013
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|